ZLDPF Zealand Pharma A/S

Zealand Pharma announces closing of collaboration and license agreement with Roche

Zealand Pharma announces closing of collaboration and license agreement with Roche

Company announcement – No. 12 / 2025

Zealand Pharma announces closing of collaboration and license agreement with Roche

Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces that all closing conditions in the collaboration and license agreement with Roche have been satisfied, including regulatory conditions, and the agreement has become effective.

“We are incredibly excited to launch this partnership, which represents a step change to realize Zealand Pharma’s vision of becoming a key player in the future management of obesity. Roche ticked all the right boxes for what we were looking for in a partner and we look very much forward to working closely together to unlock the full potential of petrelintide to benefit people who are overweight or obese”, said Adam Steensberg, Chief Executive Officer at Zealand Pharma. 

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand’s business and activities, please visit .

Contacts

Adam Lange (Investors)

Vice President, Investor Relations

Zealand Pharma

Email:

Neshat Ahmadi (Investors)

Investor Relations Manager

Zealand Pharma

Email:

Anna Krassowska, PhD (Investors and Media)

Vice President, Investor Relations & Corporate Communications

Zealand Pharma

Email: 



EN
09/05/2025

Underlying

ZLDPFZealand Pharma A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma major shareholder announcement: Van Herk Investments B....

Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Company announcement – No. 17 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, July 18, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 18 July 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 17 July 2025, Van Herk Investments B.V. (Dutch re...

July 18, 2025 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Total number of shares and voting rights in Zealand Pharma as of June ...

Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar mo...

June 30, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
ZLDPF Zealand Pharma ...

ADA amylin monotherapy highlights Zealand, Novo, Lilly

The American Diabetes Association (ADA) conference was held 20-23 June, 2025 and contained a number of highly anticipated updates in the obesity pipeline. We summarise the key amylin monotherapy datasets in this note including data from Zealand from petrelintide's phase 1b showing higher weight loss in females, Lilly's eloralintide full presentation, which shows that the higher doses which showed competitive weight loss and generated excitement following the abstract release also come with heada...

ZLDPF ZEALAND PHARMA A/S
06/24/25 June 24, 2025 1 EN
Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Thomas Couvreur
ROYAL VOPAK NV
ZLDPF ZEALAND PHARMA A/S
MAAT MAAT PHARMA SA
06/20/25 June 20, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
ZLDPF Zealand Pharma ...

Zealand Pharma We think sell off is overdone, jury is still out on elo...

Following the release of phase 1 MAD results for eloralintide (Lilly, no coverage) showing 11.3% weight loss at 12 weeks, Zealand's stock has declined -18% over the last 5 days. While the results look competitive vs. Zealand's petrelintide at first glance, key details on dosing and GI side effects per treatment arm remain undisclosed. We note that, given their similar activity on both amylin and calcitonin receptors, cagrilintide's long term 68 week data de-risks petrelintide's development. This...

ZLDPF ZEALAND PHARMA A/S
06/20/25 June 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch